an update on the MS studies would be nice considering our recent support or some details about canntab and our arrangement to supply product in australia.
TLS Telstra to boost phone plan prices despite inflation – and despite claiming they wouldn't 2 months ago
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%